Advertisement

Optimal management of hormonal contraceptives after an episode of venous thromboembolism

  • Frederikus A. Klok
    Correspondence
    Corresponding author at: Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
    Affiliations
    Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University, Mainz, Germany

    Department of Medicine - Thrombosis & Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
    Search for articles by this author
  • Stefano Barco
    Affiliations
    Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University, Mainz, Germany
    Search for articles by this author

      ABSTRACT

      Optimal management of hormonal contraception in patients with venous thromboembolism (VTE) requires an individualized approach considering its potential benefits and complications during and after anticoagulant treatment. Potential benefits include prevention of pregnancy and mitigation of menstrual bleeding that is often worsened after start of anticoagulation therapy. Current evidence suggests that patients may opt for a continuation of (all forms of) hormonal contraception during anticoagulant treatment, provided that they are adequately informed by the treating physicians. Combined oral contraceptives should be stopped before anticoagulant therapy may be discontinued, preferably after the second last menstrual cycle of the intended anticoagulant treatment period. If hormonal contraceptive treatment needs to be initiated in patients with a history of VTE, oral prostagen-only therapy or intra-uterine devices are to be preferred: this may be independent of the anticoagulation status and in light of a negligible risk of (recurrent) VTE associated with their use.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Vandenbroucke J.P.
        • Rosing J.
        • Bloemenkamp K.W.
        • et al.
        Oral contraceptives and the risk of venous thrombosis.
        N. Engl. J. Med. 2001; 344: 1527-1535
        • Canonico M.
        • Plu-Bureau G.
        • Lowe G.D.
        • Scarabin P.Y.
        Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.
        BMJ. 2008; 336: 1227-1231
        • Jick H.
        • Jick S.S.
        • Gurewich V.
        • et al.
        Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
        Lancet. 1995; 346: 1589-1593
        • Weill A.
        • Dalichampt M.
        • Raguideau F.
        • et al.
        Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study.
        BMJ. 2016; 353i2002
        • Huisman M.V.
        • Barco S.
        • Cannegieter S.C.
        • et al.
        Pulmonary embolism.
        Nat. Rev. Dis. Primers. 2018; 418028
        • Baglin T.
        • Bauer K.
        • Douketis J.
        • et al.
        Duration of anticoagulant therapy after a fi rst episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH.
        J. Thromb. Haemost. 2012; 10: 698-702
        • Klok F.A.
        • Schreiber K.
        • Stach K.
        • et al.
        Oral contraception and menstrual bleeding during treatment of venous thromboembolism: Expert opinion versus current practice.
        Combined results of a systematic review, expert panel opinion and an international survey. Thromb Res. 2017; 153: 101-107
        • Reid R.
        Clinical Practice Gynaecology Committee, SOGC clinical practice guideline. No. 252, December 2010. Oral contraceptives and the risk of venous thromboembolism: an update.
        J. Obstet. Gynaecol. Can. 2010; 32: 1192-1197
        • Middeldorp S.
        • Meijers J.C.
        • van den Ende A.E.
        • et al.
        Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.
        Thromb. Haemost. 2000; 84: 4-8
        • Tchaikovski S.N.
        • Rosing J.
        Mechanisms of estrogen-induced venous thromboembolism.
        Thromb. Res. 2010; 126: 5-11
      1. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
        Lancet. 1995; 346: 1575-1582
        • Stegeman B.H.
        • de Bastos M.
        • Rosendaal F.R.
        • et al.
        Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network metaanalysis.
        BMJ. 2013; 347: f5298
        • Lidegaard O.
        • Nielsen L.H.
        • Skovlund C.W.
        • et al.
        Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9.
        BMJ. 2011; 343: d6423
        • Dragoman M.V.
        • Tepper N.K.
        • Fu R.
        • et al.
        A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
        Int. J. Gynaecol. Obstet. 2018; 141: 287-294
        • Hugon-Rodin J.
        • Horellou M.H.
        • Conard J.
        • et al.
        Type of combined contraceptives, factor V Leiden mutation and risk of venous thromboembolism.
        Thromb. Haemost. 2018; 118: 922-928
        • Lidegaard O.
        • Nielsen L.H.
        • Skovlund C.W.
        • Lokkegaard E.
        Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10.
        BMJ. 2012; 344: e2990
        • EINSTEIN Investigators
        • Bauersachs R.
        • S.D. Berkowitz
        • et al.
        Oral rivaroxaban for symptomatic venous thromboembolism.
        N. Engl. J. Med. 2010; 363: 2499-2510
        • EINSTEIN-PE Investigators
        • Buller H.R.
        • Prins M.H.
        • et al.
        Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
        N. Engl. J. Med. 2012; 366: 1287-1297
        • Martinelli I.
        • Lensing A.W.A.
        • Middeldorp S.
        • et al.
        Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.
        Blood. 2016; 127: 1417-1425
        • Schulman S.
        • Kearon C.
        • Kakkar A.K.
        • et al.
        Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
        N. Engl. J. Med. 2009; 361: 2342-2352
        • Schulman S.
        • Kakkar A.K.
        • Goldhaber S.Z.
        • et al.
        Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
        Circulation. 2014; 129: 764-772
        • Huisman M.V.
        • Ferreira M.
        • Feuring M.
        • et al.
        Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism.
        J. Thromb. Haemost. 2018; 16: 1775-1778
        • Stam-Slob M.C.
        • Lambalk C.B.
        • van de Ree M.A.
        Contraceptive and hormonal treatment options for women with history of venous thromboembolism.
        BMJ. 2015; h4847
        • Vaillant-Roussel H.
        • Ouchchane L.
        • Dauphin C.
        • et al.
        Risk factors for recurrence of venous thromboembolism associated with the use of oral contraceptives.
        Contraception. 2011; 84: e23-e30
        • Christiansen S.C.
        • Lijfering W.M.
        • Helmerhorst F.M.
        • et al.
        Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event.
        J. Thromb. Haemost. 2010; 8: 2159-2168
        • Eischer L.
        • Eichinger S.
        • Kyrle P.A.
        The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study.
        J. Thromb. Haemost. 2014; 12: 635-640
        • Douketis J.
        • Tosetto A.
        • Marcucci M.
        • et al.
        Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis.
        BMJ. 2011; 342: d813
        • Le Gal G.
        • Kovacs M.J.
        • Carrier M.
        • et al.
        Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study.
        Thromb. Haemost. 2010; 104: 498-503
        • Salonen Ros H.
        • Lichtenstein P.
        • Bellocco R.
        • et al.
        Increased risks of circulatory diseases in late pregnancy and puerperium.
        Epidemiology. 2001; 12: 456-460
        • van Langevelde K.
        • Flinterman L.E.
        • van Hylckama Vlieg A.
        • et al.
        Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum.
        Blood. 2012; 120: 933-946
        • Barco S.K.
        • Klok F.A.
        • Mahe I.
        • et al.
        on behalf of the RIETE Investigators, Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis.
        Thromb. Res. 2019; 173: 166-171
        • Chan W.S.
        • Anand S.
        • Ginsberg J.S.
        Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature.
        Arch. Intern. Med. 2000; 160: 191-196
        • D'Souza R.
        • Ostro J.
        • Shah P.S.
        • et al.
        Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis.
        Eur. Heart J. 2017; 38: 1509-1516
        • Schaefer C.
        • Hannemann D.
        • Meister R.
        • et al.
        Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study.
        Thromb. Haemost. 2006; 95: 949-957
        • van der Hulle T.
        • Kooiman J.
        • den Exter P.L.
        • et al.
        Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and metaanalysis.
        J. Thromb. Haemost. 2014; 12: 320-328
        • van der Hulle T.
        • Dronkers C.E.
        • Klok F.A.
        • Huisman M.V.
        Recent developments in the diagnosis and treatment of pulmonary embolism.
        J. Intern. Med. 2016; 279: 16-29
        • Konstantinides S.V.
        • Torbicki A.
        • Agnelli G.
        • et al.
        2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
        Eur. Heart J. 2014; 35 (3069a-3069k): 3033-3069
        • Cohen H.
        • Arachchillage D.R.
        • Beyer-Westendorf J.
        • et al.
        Direct oral anticoagulants and women.
        Semin. Thromb. Hemost. 2016; 42: 789-797
        • Cohen H.
        • Arachchillage D.R.
        • Middeldorp S.
        • et al.
        Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH.
        J. Thromb. Haemost. 2016; 14: 1673-1676
        • Hoeltzenbein M.
        • Beck E.
        • Meixner K.
        • et al.
        Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre.
        Clin. Res. Cardiol. 2016; 105: 117-126
        • Beyer-Westendorf J.
        • Michalski F.
        • Tittl L.
        • et al.
        Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting.
        Thromb. Haemost. 2016; 116: 651-658
        • O'Brien S.H.
        • Koch T.
        • Vesely S.K.
        • Schwarz E.B.
        Hormonal contraception and risk of thromboembolism in women with diabetes.
        Diabetes Care. 2017; 40: 233-238
        • Rahn D.D.
        • Abed H.
        • Sung V.W.
        • et al.
        Systematic review highlights difficulty interpreting diverse clinical outcomes in abnormal uterine bleeding trials.
        J. Clin. Epidemiol. 2011; 64: 293-300
        • Sjalander A.
        • Friberg B.
        • Svensson P.
        • et al.
        Menorrhagia and minor bleeding symptoms in women on oral anticoagulation.
        J. Thromb. Thrombolysis. 2007; 24: 39-41
        • Huq F.Y.
        • Tvarkova K.
        • Arafa A.
        • Kadir R.A.
        Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation.
        Contraception. 2011; 84: 128-132
        • Whitaker L.
        • Critchley H.O.
        Abnormal uterine bleeding.
        Best Pract. Res. Clin. Obstet. Gynaecol. 2016; 34: 54-65
        • Davies J.
        • Kadir R.A.
        Heavy menstrual bleeding: an update on management.
        Thromb. Res. 2017; 151 (Suppl 1): S70-S77
        • Boonyawat K.
        • O'Brien S.H.
        • Bates S.M.
        How I treat heavy menstrual bleeding associated with anticoagulants.
        Blood. 2017; 130: 2603-2609
        • Klok F.A.
        • van Kralingen K.W.
        • van Dijk A.P.
        • et al.
        Quality of life in long-term survivors of acute pulmonary embolism.
        Chest. 2010; 138: 1432-1440
        • van Es J.
        • den Exter P.L.
        • Kaptein A.A.
        • et al.
        Quality of life after pulmonary embolism as assessed with SF-36 and PEmb-QoL.
        Thromb. Res. 2013; 132: 500-505
        • Klok F.A.
        • Tijmensen J.E.
        • Haeck M.L.A.
        • et al.
        Persistent dyspnea complaints at long-term follow-up after an episode of acute pulmonary embolism: results of a questionnaire.
        Eur. J. Intern. Med. 2008; 19: 625-629
        • Hunter R.
        • Noble S.
        • Lewis S.
        • Bennett P.
        Long-term psychosocial impact of venous thromboembolism: a qualitative study in the community.
        BMJ. Open. 2019; 9e024805
        • Scheres L.
        • Brekelmans M.
        • Ageno W.
        • et al.
        Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study.
        BJOG. 2018; 125: 1581-1589
        • Brekelmans M.P.
        • Scheres L.J.
        • Bleker S.M.
        • et al.
        Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
        Thromb. Haemost. 2017; 117: 809-815
        • Pisoni C.N.
        • Cuadrado M.J.
        • Khamashta M.A.
        • Hunt B.J.
        Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil).
        Lupus. 2006; 15: 877-880
        • Vilos G.A.
        • Tureanu V.
        • Garcia M.
        • Abu-Rafea B.
        The Levonorgestrel intrauterine system is an effective treatment in women with abnormal uterine bleeding and anticoagulant therapy.
        J. Minim. Invasive Gynecol. 2009; 16: 480-484
        • Braga G.C.
        • Brito M.B.
        • Ferriani R.A.
        • et al.
        Oral anticoagulant therapy does not modify the bleeding pattern associated with the levonorgestrel-releasing intrauterine system in women with thrombophilia and/or a history of thrombosis.
        Contraception. 2014; 89: 48-53
        • Kilic S.
        • Yuksel B.
        • Doganay M.
        • et al.
        The effect of levonorgestrel-releasing intrauterine device on menorrhagia in women taking anticoagulant medication after cardiac valve replacement.
        Contraception. 2009; 80: 152-157
        • Klok F.A.
        • Hosel V.
        • Clemens A.
        • et al.
        Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment.
        Eur. Respir. J. 2016; 48: 1369-1376
        • Klok F.A.
        • Kooiman J.
        • Huisman M.V.
        • et al.
        Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review.
        Eur. Respir. J. 2015; 45: 201-210
        • Klok F.A.
        • Barco S.
        • Konstantinides S.V.
        External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism.
        Thromb. Haemost. 2017; 117: 1164-1170
        • Kearon C.
        • Akl E.A.
        • Ornelas J.
        • et al.
        Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report.
        Chest. 2016; 149: 315-352
      2. (accessed 15 March 2019)